Analyze Diet
Frontiers in veterinary science2023; 10; 1256284; doi: 10.3389/fvets.2023.1256284

Intra-articular bone marrow mononuclear cell therapy improves lameness from naturally occurring equine osteoarthritis.

Abstract: Osteoarthritis (OA) can be debilitating and is related to impaired resolution of synovial inflammation. Current treatments offer temporary relief of clinical signs, but have potentially deleterious side effects. Bone marrow mononuclear cells (BMNC) are a rich source of macrophage progenitors that have the ability to reduce OA symptoms in people and inflammation in experimentally-induced synovitis in horses. The objective of this study was to evaluate the ability of intra-articular BMNC therapy to improve clinical signs of naturally occurring equine OA. Horses presenting with clinical and radiographic evidence of moderate OA in a single joint were randomly assigned to 1 of 3 treatment groups: saline (negative control), triamcinolone (positive control), or BMNC (treatment group). Lameness was evaluated subjectively and objectively, joint circumference measured, and synovial fluid collected for cytology and growth factor/cytokine quantification at 0, 7, and 21 days post-injection. Data were analyzed using General Estimating Equations with significance set at  < 0.05. There were no adverse effects noted in any treatment group. There was a significant increase in synovial fluid total nucleated cell count in the BMNC-treated group on day 7 (median 440; range 20-1920 cells/uL) compared to day 0. Mononuclear cells were the predominant cell type across treatments at all time points. Joint circumference decreased significantly in the BMNC-treated group from days 7 to 21 and was significantly lower at day 21 in the BMNC-treated group compared to the saline-treated group. Median objective lameness improved significantly in the BMNC group between days 7 and 21. GM-CSF, IL-1ra, IGF-1, and TNF-α were below detectable limits and IL-6, IL-1β, FGF-2 were detectable in a limited number of synovial fluid samples. Inconsistent and limited differences were detected over time and between treatment groups for synovial fluid PGE, SDF-1, MCP-1 and IL-10. Decreased lameness and joint circumference, coupled with a lack of adverse effects following BMNC treatment, support a larger clinical trial using BMNC therapy to treat OA in horses.
Publication Date: 2023-10-09 PubMed ID: 37876630PubMed Central: PMC10591079DOI: 10.3389/fvets.2023.1256284Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the potential use of intra-articular bone marrow mononuclear cell therapy for treating osteoarthritis in horses and reveals promising results in reducing lameness and joint inflammation.

Research Aim

  • The main objective of the study was to evaluate whether intra-articular treatment with bone marrow mononuclear cells (BMNCs) can alleviate the symptoms of natural osteoarthritis in horses. BMNCs are rich in macrophage progenitors which have been demonstrated to alleviate inflammation and symptoms of osteoarthritis in humans and experimentally-induced synovitis in horses.

Methodology

  • The study involved horses with clinically observable and radiographic evidence of moderate osteoarthritis in a single joint. They were randomly assigned to three treatment groups: saline (negative control), triamcinolone (positive control), or BMNCs (treatment group).
  • The horses’ lameness was evaluated both subjectively and objectively, the joint circumference was measured, and synovial fluid was collected for cytology and growth factor/cytokine quantification at different time points: day 0, day 7, and day 21 post-injection.

Results

  • No adverse effects were observed in any of the treatment groups.
  • A significant increase in nucleated cells in the synovial fluid was noted in the BMNC-treated group on day 7 compared to day 0, suggesting the BMNCs had entered the affected joint.
  • The joint circumference notably decreased in the BMNC-treated group from days 7 to 21, indicating a reduction of inflammation.
  • Improvement in lameness in horses was significantly higher in the BMNC group between days 7 and 21.
  • Detectable changes in synovial fluid levels of certain cells and substances were inconsistent, with some remaining below detectable limits.

Conclusion

  • This study indicates that BMNC therapy can potentially be an effective treatment for osteoarthritis in horses, reducing lameness and joint inflammation. The lack of adverse effects further supports the potential use of this treatment.
  • Thus, a larger clinical trial is required to further evaluate BMNC therapy as a treatment for osteoarthritis in horses. With the growing need for effective treatments for osteoarthritis in horses, these findings may have implications for future treatment strategies.

Cite This Article

APA
Everett JB, Menarim BC, Barrett SH, Bogers SH, Byron CR, Pleasant RS, Werre SR, Dahlgren LA. (2023). Intra-articular bone marrow mononuclear cell therapy improves lameness from naturally occurring equine osteoarthritis. Front Vet Sci, 10, 1256284. https://doi.org/10.3389/fvets.2023.1256284

Publication

ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 10
Pages: 1256284
PII: 1256284

Researcher Affiliations

Everett, J Blake
  • Department of Large Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, United States.
Menarim, Bruno C
  • Department of Large Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, United States.
  • Gluck Equine Research Center, Department of Veterinary Science, Martin-Gatton College of Agriculture, Food and Environment, University of Kentucky, Lexington, KY, United States.
Barrett, Sarah H
  • Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, United States.
Bogers, Sophie H
  • Department of Large Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, United States.
Byron, Christopher R
  • Department of Large Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, United States.
Pleasant, R Scott
  • Department of Large Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, United States.
Werre, Stephen R
  • Laboratory for Study Design and Statistical Analysis, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, United States.
Dahlgren, Linda A
  • Department of Large Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, United States.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

This article includes 79 references
  1. Murphy LB, Cisternas MG, Pasta DJ, Helmick CG, Yelin EH. Medical expenditures and earnings losses among us adults with arthritis in 2013. Arthritis Care Res (2018) 70:869–76.
    doi: 10.1002/acr.23425pubmed: 28950426google scholar: lookup
  2. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis. Bone Joint Res (2012) 1:297–309.
  3. Meeson RL, Todhunter RJ, Blunn G, Nuki G, Pitsillides AA. Spontaneous dog osteoarthritis - a one medicine vision. Nat Rev Rheumatol (2019) 15:273–87.
    doi: 10.1038/s41584-019-0202-1pmc: PMC7097182pubmed: 30953036google scholar: lookup
  4. Theis KA, Murphy LB, Guglielmo D, Boring MA, Okoro CA, Duca LM. Prevalence of arthritis and arthritis-attributable activity limitation - United States, 2016-2018. MMWR Morb Mortal Wkly Rep (2021) 70:1401–7.
    doi: 10.15585/mmwr.mm7040a2pmc: PMC8519273pubmed: 34618800google scholar: lookup
  5. Oke SMC, Moyer W. Review of the economic impact of osteoarthritis and oral joint-health supplements in horses. Proc Am Assoc Equine Pract (2010) 56:12–6.
  6. Canine Arthritis Management . Arthritis – The basics. Available at: https://caninearthritis.co.uk/what-is-arthritis/arthritis-the-basics/#:~:text=Osteoarthritis%20(OA)%20is%20the%20most,dogs%2C%20especially%20if%20left%20untreated
  7. Morris Animal Foundation . Ow, that hurts – Osteoarthritis in dogs and cats. Available at: https://www.morrisanimalfoundation.org/article/osteoarthritis-in-dogs-and-cats#:~:text=Osteoarthritis%20affects%20approximately%2014%20million,as%20a%20top%20health%20concern
  8. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone (2012) 51:249–57.
    doi: 10.1016/j.bone.2012.02.012pmc: PMC3372675pubmed: 22387238google scholar: lookup
  9. Musumeci G, Aiello FC, Szychlinska MA, Di Rosa M, Castrogiovanni P, Mobasheri A. Osteoarthritis in the XXIst century: risk factors and behaviours that influence disease onset and progression. Int J Mol Sci (2015) 16:6093–112.
    doi: 10.3390/ijms16036093pmc: PMC4394521pubmed: 25785564google scholar: lookup
  10. Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum (2010) 62:647–57.
    doi: 10.1002/art.27290pubmed: 20187160google scholar: lookup
  11. Kennedy A, Fearon U, Veale DJ, Godson C. Macrophages in synovial inflammation. Front Immunol (2011) 2:52.
    doi: 10.3389/fimmu.2011.00052pmc: PMC3342259pubmed: 22566842google scholar: lookup
  12. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther (2017) 19:18.
    doi: 10.1186/s13075-017-1229-9pmc: PMC5289060pubmed: 28148295google scholar: lookup
  13. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol (1997) 24:365–71.
    pubmed: 9034998
  14. Griffin TM, Scanzello CR. Innate inflammation and synovial macrophages in osteoarthritis pathophysiology. Clin Exp Rheumatol (2019) 37:57–63.
    pmc: PMC6842324pubmed: 31621560
  15. Wu CL, Harasymowicz NS, Klimak MA, Collins KH, Guilak F. The role of macrophages in osteoarthritis and cartilage repair. Osteoarthr Cartil (2020) 28:544–54.
    doi: 10.1016/j.joca.2019.12.007pmc: PMC7214213pubmed: 31926267google scholar: lookup
  16. Manferdini C, Paolella F, Gabusi E, Silvestri Y, Gambari L, Cattini L. From osteoarthritic synovium to synovial-derived cells characterization: synovial macrophages are key effector cells. Arthritis Res Ther (2016) 18:83.
    doi: 10.1186/s13075-016-0983-4pmc: PMC4820904pubmed: 27044395google scholar: lookup
  17. Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther (2006) 8:R187.
    doi: 10.1186/ar2099pmc: PMC1794533pubmed: 17177994google scholar: lookup
  18. Menarim BC, MacLeod JN, Dahlgren LA. Bone marrow mononuclear cells for joint therapy: the role of macrophages in inflammation resolution and tissue repair. World J Stem Cells (2021) 13:825–40.
    doi: 10.4252/wjsc.v13.i7.825pmc: PMC8316866pubmed: 34367479google scholar: lookup
  19. Orlowsky EW, Kraus VB. The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive. J Rheumatol (2015) 42:363–71.
    doi: 10.3899/jrheum.140382pmc: PMC4465583pubmed: 25593231google scholar: lookup
  20. Fichadiya A, Bertram KL, Ren G, Yates RM, Krawetz RJ. Characterizing heterogeneity in the response of synovial mesenchymal progenitor cells to synovial macrophages in normal individuals and patients with osteoarthritis. J Inflamm (2016) 13:12.
    doi: 10.1186/s12950-016-0120-9pmc: PMC4823907pubmed: 27057150google scholar: lookup
  21. Murray PJ. Macrophage polarization. Annu Rev Physiol (2017) 79:541–66.
  22. Uderhardt S, Martins AJ, Tsang JS, Lammermann T, Germain RN. Resident macrophages cloak tissue microlesions to prevent neutrophil-driven inflammatory damage. Cells (2019) 177:e17: 541–555.e17.
    doi: 10.1016/j.cell.2019.02.028pmc: PMC6474841pubmed: 30955887google scholar: lookup
  23. Culemann S, Gruneboom A, Nicolas-Avila JA, Weidner D, Lammle KF, Rothe T. Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature (2019) 572:670–5.
    doi: 10.1038/s41586-019-1471-1pmc: PMC6805223pubmed: 31391580google scholar: lookup
  24. Souza MV. Osteoarthritis in horses - part 2: a review of the intra-articular use of corticosteroids as a method of treatment. Braz Arch Biol Technol (2016) 59:59.
  25. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity (2014) 40:315–27.
  26. Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of inflammation: what controls its onset?. Front Immunol (2016) 40:212–27.
    doi: 10.1016/j.it.2019.01.007pmc: PMC4845539pubmed: 27199985google scholar: lookup
  27. Kydd AS, Reno CR, Tsao HW, Hart DA. Early inflammatory arthritis in the rabbit: the influence of intraarticular and systemic corticosteroids on mRNA levels in connective tissues of the knee. J Rheumatol (2007) 34:130–9.
    pubmed: 17117483
  28. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res (2007) 68:290–6.
    doi: 10.2460/ajvr.68.3.290pubmed: 17331019google scholar: lookup
  29. Lasarzik J, Bondzio A, Rettig M, Estrada R, Klaus C, Ehrle A. Evaluation of two protocols using autologous conditioned serum for intra-articular therapy of equine osteoarthritis—a pilot study monitoring cytokines and cartilage-specific biomarkers. J Equine Vet (2018) 60:35–42.e2.
  30. Broeckx SY, Seys B, Suls M, Vandenberghe A, Marien T, Adriaensen E. Equine allogeneic chondrogenic induced mesenchymal stem cells are an effective treatment for degenerative joint disease in horses. Stem Cells Dev (2019) 28:410–22.
    doi: 10.1089/scd.2018.0061pmc: PMC6441287pubmed: 30623737google scholar: lookup
  31. Colbath AC, Dow SW, Hopkins LS, Phillips JN, McIlwraith CW, Goodrich LR. Induction of synovitis using interleukin-1 beta: are there differences in the response of middle carpal joint compared to the tibiotarsal joint?. Front Vet Sci (2018) 5:208.
    doi: 10.3389/fvets.2018.00208pmc: PMC6127273pubmed: 30234134google scholar: lookup
  32. Cruz FF, Borg ZD, Goodwin M, Coffey AL, Wagner DE, Rocco PR. CD11b+ and Sca-1+ cells exert the main beneficial effects of systemically administered bone marrow-derived mononuclear cells in a murine model of mixed Th2/Th17 allergic airway inflammation. Stem Cells Transl Med (2016) 5:488–99.
    doi: 10.5966/sctm.2015-0141pmc: PMC4798733pubmed: 26933041google scholar: lookup
  33. Nguyen TL, Nguyen HP, Nguyen TK. The effects of bone marrow mononuclear cell transplantation on the quality of life of children with cerebral palsy. Health Qual Life Outcomes (2018) 16:164.
    doi: 10.1186/s12955-018-0992-xpmc: PMC6092872pubmed: 30107811google scholar: lookup
  34. Singh A, Gangwar DS, Singh S. Bone marrow injection: a novel treatment for tennis elbow. J Nat Sci Biol Med (2014) 5:389–91.
    doi: 10.4103/0976-9668.136198pmc: PMC4121921pubmed: 25097421google scholar: lookup
  35. Shizhu J, Xiangwei M, Xun S, Mingzi H, Bingrong L, Dexia K. Bone marrow mononuclear cell transplant therapy in mice with CCl4-induced acute liver failure. Turk J Gastroenterol (2012) 23:344–52.
    doi: 10.4318/tjg.2012.0344pubmed: 22965505google scholar: lookup
  36. Giraldi-Guimaraes A, de Freitas HT, Coelho Bde P, Macedo-Ramos H, Mendez-Otero R, Cavalcante LA. Bone marrow mononuclear cells and mannose receptor expression in focal cortical ischemia. Brain Res (2012) 1452:173–84.
  37. Song F, Tang J, Geng R, Hu H, Zhu C, Cui W. Comparison of the efficacy of bone marrow mononuclear cells and bone mesenchymal stem cells in the treatment of osteoarthritis in a sheep model. Int J Clin Exp Pathol (2014) 7:1415–26.
    pmc: PMC4014221pubmed: 24817937
  38. Oh BJ, Jin SM, Hwang Y, Choi JM, Lee HS, Kim G. Highly angiogenic, nonthrombogenic bone marrow mononuclear cell-derived spheroids in intraportal islet transplantation. Diabetes (2018) 67:473–85.
    doi: 10.2337/db17-0705pubmed: 29298810google scholar: lookup
  39. Olingy CE, San Emeterio CL, Ogle ME, Krieger JR, Bruce AC, Pfau DD. Non-classical monocytes are biased progenitors of wound healing macrophages during soft tissue injury. Sci Rep (2017) 7:447.
    doi: 10.1038/s41598-017-00477-1pmc: PMC5428475pubmed: 28348370google scholar: lookup
  40. Menarim BC, El-Sheikh Ali H, Loux SC, Scoggin KE, Kalbfleisch TS, MacLeod JN. Transcriptional and histochemical signatures of bone marrow mononuclear cell-mediated resolution of synovitis. Front Immunol (2021) 12:734322.
    doi: 10.3389/fimmu.2021.734322pmc: PMC8692379pubmed: 34956173google scholar: lookup
  41. Menarim BC, Gillis KH, Oliver A, Mason C, Ngo Y, Werre SR. Autologous bone marrow mononuclear cells modulate joint homeostasis in an equine in vivo model of synovitis. FASEB J (2019) 33:14337–53.
    doi: 10.1096/fj.201901684RRpubmed: 31665925google scholar: lookup
  42. Goncars V, Jakobsons E, Blums K, Briede I, Patetko L, Erglis K. The comparison of knee osteoarthritis treatment with single-dose bone marrow-derived mononuclear cells vs. hyaluronic acid injections. Medicina (2017) 53:101–8.
    doi: 10.1016/j.medici.2017.02.002pubmed: 28416171google scholar: lookup
  43. Goncars V, Kalnberzs K, Jakobsons E, Engele I, Briede I, Blums K. Treatment of knee osteoarthritis with bone marrow-derived mononuclear cell injection: 12-month follow-up. Cartilage (2019) 10:26–35.
    doi: 10.1177/1947603517746721pmc: PMC6376566pubmed: 29373926google scholar: lookup
  44. Menarim BC, Gillis KH, Oliver A, Mason C, Werre SR, Luo X. Inflamed synovial fluid induces a homeostatic response in bone marrow mononuclear cells in vitro: implications for joint therapy. FASEB J (2020) 34:4430–44.
    doi: 10.1096/fj.201902698Rpubmed: 32030831google scholar: lookup
  45. Barussi FC, Bastos FZ, Leite LM, Fragoso FY, Senegaglia AC, Brofman PR. Intratracheal therapy with autologous bone marrow-derived mononuclear cells reduces airway inflammation in horses with recurrent airway obstruction. Respir Physiol Neurobiol (2016) 232:35–42.
    doi: 10.1016/j.resp.2016.07.002pubmed: 27396936google scholar: lookup
  46. Wang C, Yu X, Cao Q, Wang Y, Zheng G, Tan TK. Characterization of murine macrophages from bone marrow, spleen and peritoneum. BMC Immunol (2013) 14:6.
    doi: 10.1186/1471-2172-14-6pmc: PMC3574850pubmed: 23384230google scholar: lookup
  47. Poulsen RC, Gotlinger KH, Serhan CN, Kruger MC. Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake. Am J Hematol (2008) 83:437–45.
    doi: 10.1002/ajh.21170pubmed: 18429055google scholar: lookup
  48. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol (2008) 8:349–61.
    doi: 10.1038/nri2294pmc: PMC2744593pubmed: 18437155google scholar: lookup
  49. Behrendt P, Feldheim M, Preusse-Prange A, Weitkamp JT, Haake M, Eglin D. Chondrogenic potential of IL-10 in mechanically injured cartilage and cellularized collagen ACI grafts. Osteoarthr Cartil (2018) 26:264–75.
    doi: 10.1016/j.joca.2017.11.007pubmed: 29169959google scholar: lookup
  50. Iannone F, De Bari C, Dell'Accio F, Covelli M, Cantatore FP, Patella V. Interleukin-10 and interleukin-10 receptor in human osteoarthritic and healthy chondrocytes. Clin Exp Rheumatol (2001) 19:139–45.
    pubmed: 11332442
  51. Ross MW. Movement. In: Ross MW, Dyson SJ, editors. Diagnosis and management of lameness in the horse. Second ed. St. Louis, MO: Elsevier/Saunders; (2011). 64–80.
  52. Holzer N, Salvo D, Marijnissen AC, Vincken KL, Ahmad AC, Serra E. Radiographic evaluation of posttraumatic osteoarthritis of the ankle: the Kellgren-Lawrence scale is reliable and correlates with clinical symptoms. Osteoarthr Cartil (2015) 23:363–9.
    doi: 10.1016/j.joca.2014.11.010pubmed: 25463444google scholar: lookup
  53. Keegan KG, Dent EV, Wilson DA, Janicek J, Kramer J, Lacarrubba A. Repeatability of subjective evaluation of lameness in horses. Equine Vet J (2010) 42:92–7.
    doi: 10.2746/042516409X479568pubmed: 20156242google scholar: lookup
  54. Keegan KG, Wilson DA, Kramer J, Reed SK, Yonezawa Y, Maki H. Comparison of a body-mounted inertial sensor system-based method with subjective evaluation for detection of lameness in horses. Am J Vet Res (2013) 74:17–24.
    doi: 10.2460/ajvr.74.1.17pubmed: 23270341google scholar: lookup
  55. Reed SK, Kramer J, Thombs L, Pitts JB, Wilson DA, Keegan KG. Comparison of results for body-mounted inertial sensor assessment with final lameness determination in 1,224 equids. J Am Vet Med Assoc (2020) 256:590–9.
    doi: 10.2460/javma.256.5.590pubmed: 32068513google scholar: lookup
  56. Rettig MJ, Leelamankong P, Rungsri P, Lischer CJ. Effect of sedation on fore- and hindlimb lameness evaluation using body-mounted inertial sensors. Equine Vet J (2016) 48:603–7.
    doi: 10.1111/evj.12463pubmed: 26032237google scholar: lookup
  57. Corrêa F, Borlone C, Wittwer F, Bustamante H, Müller A, Ramírez A. How to obtain and isolate equine sternal bone marrow mononuclear cells with limited resources. Arch Med Vet (2014) 46:471–6.
  58. Correa-Letelier L, Galecio J, Bustamante H, Ramirez A, Menarim B. Mononuclear cells concentration in fractioned samples of bone marrow aspirate of horse’s sternum. Vet Clin Pathol (2012) 41:E1–E47.
  59. Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol (2001) Appendix 3:Appendix 3B.
    doi: 10.1002/0471142735.ima03bs21pubmed: 18432654google scholar: lookup
  60. Menarim BC, Gillis KH, Oliver A, Ngo Y, Werre SR, Barrett SH. Macrophage activation in the synovium of healthy and osteoarthritic equine joints. Front Vet Sci (2020) 7:568756.
    doi: 10.3389/fvets.2020.568756pmc: PMC7726135pubmed: 33324696google scholar: lookup
  61. McIlwraith CW. Intraarticular Corticosteroids. In: McIlwraith CW, Frisbie DD, Kawcak CE, Weeren PR, editors. Joint disease in the horse. Second Edition. Edinburgh: W.B. Saunders; (2016). p. 202–214.
  62. Chuang CH, Kuo CC, Chiang YF, Lee PY, Wang FH, Hsieh CY. Enriched peripheral blood-derived mononuclear cells for treating knee osteoarthritis. Cell Transplant (2023) 32:9636897221149445.
    doi: 10.1177/09636897221149445pmc: PMC9903009pubmed: 36661223google scholar: lookup
  63. Andreassen SM, Vinther AML, Nielsen SS, Andersen PH, Tnibar A, Kristensen AT. Changes in concentrations of haemostatic and inflammatory biomarkers in synovial fluid after intra-articular injection of lipopolysaccharide in horses. BMC Vet Res (2017) 13:182.
    doi: 10.1186/s12917-017-1089-1pmc: PMC5477303pubmed: 28629364google scholar: lookup
  64. Kemble S, Croft AP. Critical role of synovial tissue-resident macrophage and fibroblast subsets in the persistence of joint inflammation. Front Immunol (2021) 12:715894.
    doi: 10.3389/fimmu.2021.715894pmc: PMC8446662pubmed: 34539648google scholar: lookup
  65. Kamm JL, Nixon AJ, Witte TH. Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naturally osteoarthritic equine carpi. Equine Vet J (2010) 42:693–9.
  66. Jayadev C, Rout R, Price A, Hulley P, Mahoney D. Hyaluronidase treatment of synovial fluid to improve assay precision for biomarker research using multiplex immunoassay platforms. J Immunol Methods (2012) 386:22–30.
    doi: 10.1016/j.jim.2012.08.012pubmed: 22955210google scholar: lookup
  67. Giesbrecht K, Eberle ME, Wolfle SJ, Sahin D, Sahr A, Oberhardt V. IL-1beta as mediator of resolution that reprograms human peripheral monocytes toward a suppressive phenotype. Front Immunol (2017) 8:899.
    doi: 10.3389/fimmu.2017.00899pmc: PMC5540955pubmed: 28824627google scholar: lookup
  68. Manferdini C, Maumus M, Gabusi E, Piacentini A, Filardo G, Peyrafitte JA. Adipose-derived mesenchymal stem cells exert antiinflammatory effects on chondrocytes and synoviocytes from osteoarthritis patients through prostaglandin E2. Arthritis Rheum (2013) 65:1271–81.
    doi: 10.1002/art.37908pubmed: 23613363google scholar: lookup
  69. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol (2006) 177:7303–11.
    doi: 10.4049/jimmunol.177.10.7303pubmed: 17082649google scholar: lookup
  70. Siebelt M, Korthagen N, Wei W, Groen H, Bastiaansen-Jenniskens Y, Muller C. Triamcinolone acetonide activates an anti-inflammatory and folate receptor-positive macrophage that prevents osteophytosis in vivo. Arthritis Res Ther (2015) 17:352.
    doi: 10.1186/s13075-015-0865-1pmc: PMC4670534pubmed: 26637220google scholar: lookup
  71. Mozo G, del Olmo ML, Caro-Paton A, Reyes E, Manzano L, Belmonte A. Pulmonary injuries and cytokine levels after the intraperitoneal administration of pancreatic homogenates in rats. Rev Esp Enferm Dig (2004) 96:33–8.
  72. Perretti M, Norling LV. Actions of SPM in regulating host responses in arthritis. Mol Asp Med (2017) 58:57–64.
    doi: 10.1016/j.mam.2017.04.005pubmed: 28456616google scholar: lookup
  73. Caron JP, Gandy JC, Brown JL, Sordillo LM. Omega-3 fatty acids and docosahexaenoic acid oxymetabolites modulate the inflammatory response of equine recombinant interleukin1beta-stimulated equine synoviocytes. Prostaglandins Other Lipid Mediat (2019) 142:1–8.
  74. van der Vlist M, Raoof R, Willemen H, Prado J, Versteeg S, Martin Gil C. Macrophages transfer mitochondria to sensory neurons to resolve inflammatory pain. Neuron (2022) 110:613–26.e9.
    doi: 10.1016/j.neuron.2021.11.020pubmed: 34921782google scholar: lookup
  75. McCracken MJ, Kramer J, Keegan KG, Lopes M, Wilson DA, Reed SK. Comparison of an inertial sensor system of lameness quantification with subjective lameness evaluation. Equine Vet J (2012) 44:652–6.
  76. Keegan KG, Yonezawa Y, Pai PF, Wilson DA, Kramer J. Evaluation of a sensor-based system of motion analysis for detection and quantification of forelimb and hind limb lameness in horses. Am J Vet Res (2004) 65:665–70.
    doi: 10.2460/ajvr.2004.65.665pubmed: 15141889google scholar: lookup
  77. Bar-Or D, Rael LT, Brody EN. Use of saline as a placebo in intra-articular injections in osteoarthritis: potential contributions to nociceptive pain relief. Open Rheumatol J (2017) 11:16–22.
    doi: 10.2174/1874312901711010016pmc: PMC5366377pubmed: 28400868google scholar: lookup
  78. Saltzman BM, Leroux T, Meyer MA, Basques BA, Chahal J, Bach BR Jr. The therapeutic effect of intra-articular normal saline injections for knee osteoarthritis: a meta-analysis of evidence level 1 studies. Am J Sports Med (2017) 45:2647–53.
    doi: 10.1177/0363546516680607pubmed: 28027657google scholar: lookup
  79. Huang QQ, Doyle R, Chen SY, Sheng Q, Misharin AV, Mao Q. Critical role of synovial tissue-resident macrophage niche in joint homeostasis and suppression of chronic inflammation. Sci Adv (2021) 7:7.
    doi: 10.1126/sciadv.abd0515pmc: PMC7787490pubmed: 33523968google scholar: lookup

Citations

This article has been cited 0 times.